The studies failed to demonstrate efficacy in the proposed indication at the dosage (200mg/ 10ml) mentioned in the summary of product characteristics as defined in Article 4a of Council Directive2 65/ 65/ EEC of 26 January 1965 and there is significant concern about the safety of parenteral infusions under normal clinical conditions of use at the dosage proposed.